Search

Displaying results 131 - 140 of 6090 in total
  1. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

    Products: BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL
  2. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    As patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures

    Products: Nuwiq 250IU Powder for Solution for Injection, Nuwiq 500IU Powder for Solution for Injection
  3. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). … [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).

    Products: EVRYSDI POWDER FOR ORAL SOLUTION 0.75 MG/ML, Evrysdi Powder for oral solution 0.75 mg/mL
  4. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). … Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are

    Products: Ilaris Powder for Solution for Injection 150mg/vial, ILARIS 150MG POWDER FOR SOLUTION FOR INJECTION
  5. Drug

    Deferoxamine

    go.drugbank.com/drugs/DB00746
    ApprovedInvestigational

    Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

    Products: Desferal 500mg Powder for Solution for Injection, Deferoxamine Mesylate for Injection
  6. Drug

    Teclistamab

    go.drugbank.com/drugs/DB16655
    ApprovedInvestigational

    [A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking

    Products: Tecvayli 90 mg/mL Solution for Injection, Tecvayli 10 mg/mL Solution for Injection
  7. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer.

    Mixtures: PHESGO Solution for Subcutaneous Injection 600mg/600mg/10mL, PHESGO Solution for Subcutaneous Injection 1200mg/600mg/15mLProducts: PERJETA CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/14ML, Perjeta 420 mg concentrate for solution for infusion
  8. Drug

    Corifollitropin alfa

    go.drugbank.com/drugs/DB09066
    ApprovedInvestigational

    FDA for its New Drug Application for this drug. Corifollitropin alfa is marketed as Elonva in more than 75 countries [L2272].

    Products: Elonva Solution for Injection 150mcg/0.5ml, Elonva Solution for Injection 100mcg/0.5ml
  9. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was gra...

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Tigaciv 50mg Lyophilized Powder for Concentrate for Solution for Infusion, TIGECYCLINE SANDOZ POWDER FOR SOLUTION FOR INFUSION 50 MG PER VIAL
  10. Drug

    Tozinameran

    go.drugbank.com/drugs/DB15696
    ApprovedInvestigational

    It is designed to induce immunity against SARS-CoV-2, the virus responsible for causing COVID-19. … [L26956] Fact sheets for caregivers, recipients, and healthcare providers are now available.

    Mixtures: Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose Concentrate for Dispersion for Injection, Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose Dispersion for InjectionProducts: Comirnaty 3mcg Concentrate for Dispersion for Injection, Comirnaty LP.8.1 30 micrograms/dose Dispersion for Injection